FDA NDA · NDA202157

LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE

Sponsor: HETERO LABS UNIT III

APPLICATION

NDA202157

TYPE

NDA

ROUTE

ORAL

DOSAGE FORM

TABLET

MARKETING STATUS

None (Tentative Approval)

Products

LAMIVUDINE; NEVIRAPINE; ZIDOVUDINENone (Tentative Approval)

LAMIVUDINE 150MG, NEVIRAPINE 200MG, ZIDOVUDINE 300MG · TABLET · ORAL

2011-11-18Type 5 - New Formulation or New Manufacturer · Original · standard — Letter ↗TA

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.